Table 1.
Characteristics of study population
| Patient parameter | NGT (N = 21) | T2DM (N = 19) | P‐value |
|---|---|---|---|
| Age (y) | 45 ± 9 | 51 ± 8 | NS |
| Sex (M/F) | 9/12 | 11/8 | NS |
| Ethnicity (H/B/C) | 17/1/3 | 14/1/5 | NS |
| Diabetes duration (y) | NA | 3.4 ± 2.5 | |
| Weight (kg) | 73.4 ± 14.3 | 87.6 ± 12.8 | .0006 |
| Body mass index (kg·m−2) | 26.9 ± 3.9 | 31.7 ± 4.7 | .0004 |
| Body surface area (m2) | 1.82 ± 0.2 | 2.00 ± 0.2 | .001 |
| Body Fat (%) | 31.8 ± 8.5 | 34.7 ± 7.3 | NS |
| Waist circumference (cm) | 93.2 ± 11 | 105.2 ± 10.7 | .001 |
| Total cholesterol (mg·dL−1) | 177 ± 26 | 177 ± 51.4 | NS |
| HbA1c (%) | 5.4 ± 0.4 | 7.1 ± 1.4 | .0001 |
| Fasting plasma glucose (mg·dL−1) | 92 ± 6 | 151 ± 44 | .0001 |
| Triglycerides (mg·dL−1) | 110 ± 82 | 217 ± 146 | .002 |
| HDL (mg·dL−1) | 55 ± 11 | 42 ± 13 | .001 |
| LDL (mg·dL−1) | 102 ± 20 | 88 ± 25 | .03 |
| Systolic blood pressure (mm Hg) | 115 ± 10 | 123 ± 10 | .01 |
| Diastolic blood pressure (mm Hg) | 75 ± 8 | 79 ± 9 | .04 |
| Heart rate (bpm) | 62 ± 9 | 69 ± 11 | NS |
| Smoking (N;%) | 2 (10%) | 5 (26%) | NS |
| Medications (N;%) | |||
| Antidiabetic Medications | |||
| Metformin | — | 14 (74%) | — |
| Sitagliptin | — | 1 (5%) | — |
| Glipizide | — | 9 (47%) | — |
| Statins | — | 16 (84%) | — |
| Fibrates | — | 1 (5%) | — |
| Niacin | — | 2 (11%) | — |
| Antiplatelet drugs | — | 15 (79%) | — |
| ACE Inhibitors/ARBs | — | 14 (74%) | — |
| Ca antagonists | — | 2 (11%) | — |
| Beta‐blockers | — | 12 (63%) | — |
| Diuretics | — | 1 (5%) | — |
Data are presented as mean ± SD or n (%).
B, Blacks; C, Caucasian; H, Hispanics.